[
  {
    "ts": null,
    "headline": "Fidelity Magellan Fund Q4 2024 Review",
    "summary": "For the final quarter of 2024, the fund gained 1.08%, trailing the 2.41% advance of the benchmark S&P 500Â® index. Read more here.",
    "url": "https://finnhub.io/api/news?id=8bff7b12d667384fef403a8b91541138f8785e23af01847cf6ae1f7cd941c6ca",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741296240,
      "headline": "Fidelity Magellan Fund Q4 2024 Review",
      "id": 133084019,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1824400059/image_1824400059.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "For the final quarter of 2024, the fund gained 1.08%, trailing the 2.41% advance of the benchmark S&P 500Â® index. Read more here.",
      "url": "https://finnhub.io/api/news?id=8bff7b12d667384fef403a8b91541138f8785e23af01847cf6ae1f7cd941c6ca"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Lunch: AI Showdown On The Cards",
    "summary": "Chinese companies are continuing to make big strides in artificial intelligence, as Alibaba (BABA) unveiled its latest reasoning model with fewer parameters.",
    "url": "https://finnhub.io/api/news?id=bfc75aa7960863d63c49fc5f8320f3f9ee42bc82ec18f768c3f50361651c3d3e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741275420,
      "headline": "Wall Street Lunch: AI Showdown On The Cards",
      "id": 133068843,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1020075066/image_1020075066.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Chinese companies are continuing to make big strides in artificial intelligence, as Alibaba (BABA) unveiled its latest reasoning model with fewer parameters.",
      "url": "https://finnhub.io/api/news?id=bfc75aa7960863d63c49fc5f8320f3f9ee42bc82ec18f768c3f50361651c3d3e"
    }
  },
  {
    "ts": null,
    "headline": "Fidelity Fund Q4 2024 Review",
    "summary": "For the three months ending December 31, 2024, the fund's Retail Class shares gained 1.53%, versus the 2.41% result of the benchmark S&P 500Â® index. Read more here.",
    "url": "https://finnhub.io/api/news?id=f6c7965a57a378b7c3260bdbdf6042c90eb3e91682e79297f7fef9b0c870fcc9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741267020,
      "headline": "Fidelity Fund Q4 2024 Review",
      "id": 133067501,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1688767071/image_1688767071.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "For the three months ending December 31, 2024, the fund's Retail Class shares gained 1.53%, versus the 2.41% result of the benchmark S&P 500Â® index. Read more here.",
      "url": "https://finnhub.io/api/news?id=f6c7965a57a378b7c3260bdbdf6042c90eb3e91682e79297f7fef9b0c870fcc9"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers Stock Is Due for a Crash Diet. The Weight-Loss Drug Surge Is Fading Fast.",
    "summary": "Hims & Hers Stock Is Due for a Crash Diet. The Weight-Loss Drug Surge Is Fading Fast.",
    "url": "https://finnhub.io/api/news?id=9daa00bf8b2cd35bd40b7ec4f47d0d97a0ee6f35efe2a529b9888136701cc73c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741252020,
      "headline": "Hims & Hers Stock Is Due for a Crash Diet. The Weight-Loss Drug Surge Is Fading Fast.",
      "id": 133052533,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Hims & Hers Stock Is Due for a Crash Diet. The Weight-Loss Drug Surge Is Fading Fast.",
      "url": "https://finnhub.io/api/news?id=9daa00bf8b2cd35bd40b7ec4f47d0d97a0ee6f35efe2a529b9888136701cc73c"
    }
  },
  {
    "ts": null,
    "headline": "LifeMD Integrates With LillyDirect to Offer Access of Single-dose Vials of Zepbound",
    "summary": "LifeMD Integrates With LillyDirect to Offer Access of Single-dose Vials of Zepbound",
    "url": "https://finnhub.io/api/news?id=766d32e7104797ef374ed9bb709ce28439f897dfd96ef719eb852b58ccbc9151",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741251060,
      "headline": "LifeMD Integrates With LillyDirect to Offer Access of Single-dose Vials of Zepbound",
      "id": 133052534,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "LifeMD Integrates With LillyDirect to Offer Access of Single-dose Vials of Zepbound",
      "url": "https://finnhub.io/api/news?id=766d32e7104797ef374ed9bb709ce28439f897dfd96ef719eb852b58ccbc9151"
    }
  }
]